A detailed history of Abingworth LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Abingworth LLP holds 2,457,500 shares of VRNA stock, worth $111 Million. This represents 21.3% of its overall portfolio holdings.

Number of Shares
2,457,500
Previous 2,457,500 -0.0%
Holding current value
$111 Million
Previous $25.1 Million 155.92%
% of portfolio
21.3%
Previous 8.58%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$3.55 - $5.06 $3 - $5
1 Added 0.0%
2,457,500 $10.2 Million
Q3 2020

Nov 16, 2020

BUY
$4.45 - $10.2 $6.92 Million - $15.9 Million
1,555,556 Added 172.47%
2,457,499 $15.3 Million
Q3 2018

Nov 14, 2018

BUY
$11.65 - $14.1 $10.5 Million - $12.7 Million
901,943 New
901,943 $11.3 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.76B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.